Paliperidone 3-Month Im Injection Suppliers & Bulk Manufacturers

Available Forms: Once-3-Month IM Injection

Available Strengths: 273 mg, 410 mg, 546 mg, 819 mg

Reference Brands: Trevicta®(EU); Invega Trinza®(US)

Category: Antipsychotropic Drugs

Paliperidone is an atypical antipsychotic that works by antagonizing dopamine D2 and serotonin 5-HT2A receptors, helping to reduce psychotic symptoms and stabilize mood. The 3-month intramuscular injection is used for the maintenance treatment of schizophrenia in adults who are already stabilized on the 1-month formulation. It ensures consistent therapeutic levels, improves patient adherence, and lowers relapse risk by reducing dosing frequency to four times a year. Paliperidone 3-Month IM Injection is available in Once-3-Month IM Injection and strengths such as 273 mg, 410 mg, 546 mg, 819 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Paliperidone 3-Month IM Injection is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Paliperidone 3-Month IM Injection can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Paliperidone 3-month intramuscular injection (brand name: Invega Trinza) is FDA-approved in the United States for the maintenance treatment of schizophrenia in adults who have been stabilized on Invega Sustenna (1-month formulation) for at least four months. In the European Union, it is centrally approved by the EMA with established Risk Management Plans (RMPs) and required pharmacovigilance activities. Regulatory compliance includes GMP-certified long-acting injectable manufacturing, bridging pharmacokinetic and safety data, and documentation for relapse prevention. U.S. labeling includes a boxed warning for elderly patients with dementia-related psychosis. Explore dossier-ready options at Pharmatradz.com — your global B2B pharma hub.